These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. Pedersen SS; Jensen T; Hvidberg EF J Antimicrob Chemother; 1987 Oct; 20(4):575-83. PubMed ID: 3479419 [TBL] [Abstract][Full Text] [Related]
6. Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning. Redmond A; Sweeney L; MacFarland M; Mitchell M; Daggett S; Kubin R J Int Med Res; 1998 Dec; 26(6):304-12. PubMed ID: 10399112 [TBL] [Abstract][Full Text] [Related]
7. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830 [TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. Stass H; Delesen H; Nagelschmitz J; Staab D J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456 [TBL] [Abstract][Full Text] [Related]
9. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118 [TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal. LeBel M Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):316-24. PubMed ID: 1907546 [TBL] [Abstract][Full Text] [Related]
12. Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. Shah A; Liu MC; Vaughan D; Heller AH J Antimicrob Chemother; 1999 Mar; 43 Suppl A():49-54. PubMed ID: 10225572 [TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326 [TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. Papich MG Am J Vet Res; 2012 Jul; 73(7):1085-91. PubMed ID: 22738062 [TBL] [Abstract][Full Text] [Related]
15. Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects. Khan MK; Khan MF Pak J Pharm Sci; 2009 Jan; 22(1):1-7. PubMed ID: 19168412 [TBL] [Abstract][Full Text] [Related]